Cancer Immunotherapy and Biomarkers

IMMUNIA identifies immunoregulatory surfaceome genes using multi-LLM reasoning, highlighting novel stromal immune checkpoint regulators.

This study uses spatial transcriptomics to identify CD8+ T cell-driven mechanisms of kidney damage in ICI-AIN, showing increased IFN-γ signaling and proinflammatory myeloid cell activation.

The paper develops computational tools to identify cancer-reactive T cells and neoantigen-specific TCRs, showing their variability across cancer types and predictive value for immunotherapy response.

This study shows that CRISPR suppression of NUTM1 promotes differentiation and increases TROP2 in NUT carcinoma cells, enhancing immunocytokine response and improving clinical outcomes.

This study shows that targeting drug-sensitive cancer cells with G12Ci inhibitors and combining it with immune therapies can eliminate drug-resistant subclones through immune-mediated bystander killing.

This study examines how CD8 T cells with different metabolic profiles contribute to tumor cure in hot versus cold murine tumors using radio-immunotherapy.

The paper identifies neuronal mimicry in cancer-associated fibroblasts driven by calcium waves, leading to immune exclusion, and shows that blocking this process restores immune control.

This paper identifies microbial transcriptional reprogramming in tumors that generates tumor-specific epitopes, enhancing immunotherapy safety by enabling targeted T cell responses.

This study shows CD8 T cells eliminate neoantigen+ epithelial stem cells in the colon, preventing cancer, without causing immunopathology.

This study uses gene regulatory network and trajectory inference to analyze single-cell RNA-seq data from squamous cell carcinoma, revealing how PD-1 blockade reprograms T cell states and identifies key transcriptional regulators.

This study identifies two immune archetypes in HRD tumors—immune-inflamed and immune-evasive—linked to chromosomal instability and lineage, informing biomarker-driven therapies.

The paper identifies somatic TYK2 mutations in TILs that enhance anti-cancer immunity and shows their therapeutic potential through mouse models.

This study shows that combining MCL1 and caspase inhibition enhances anti-tumor immunity in breast cancer by activating the cGAS-STING pathway and remodeling the tumor microenvironment.

This study identifies Bhlhe40 as a key regulator of T cell effector differentiation, showing distinct roles in CD4 and CD8 T cells for anti-PD-1 and anti-CTLA-4 therapies.

This study identifies TAK1 as a therapeutic target in pancreatic cancer that enhances anti-tumor immunity and sensitizes tumors to checkpoint blockade.

This study examines the dynamic changes in the immune microenvironment of paediatric solid tumours over time, revealing a shift toward immunosuppressive and tolerogenic states.

This study shows that radiation-induced podoplanin-positive fibroblasts limit CD8+ T-cell access to tumour cells, reducing radiotherapy effectiveness, and that disrupting PDPN signaling enhances tumour control.

This study identifies BPU11, a small molecule CD28 antagonist that disrupts CD28-B7 interactions and suppresses T-cell activation, offering a new approach to immune checkpoint blockade.

The paper compares radiation response in autochthonous and transplant sarcomas in mice with and without adaptive immunity, finding higher cure rates in transplant tumors with immune function.

The paper analyzes ORF1p expression across cancers, finding it correlates with immune suppression in some tumors and activation in others, linked to copy number alterations.

The paper identifies ETV4 as a transcription factor that restricts cytotoxic exhausted CD8+ T cell differentiation and shows CD74+ Tex cells correlate with improved survival.

This study shows liver metastases reduce checkpoint inhibitor efficacy by increasing splenic granulopoiesis and S100A9hi neutrophils, which suppress T-cell responses, and demonstrates that targeting S100A9 restores efficacy.

This study identifies NEPN as a tumor-suppressive embryonic factor that enhances cancer immunotherapy by modulating TGFβ1 signaling and immune responses in both non-solid and solid tumors.

This study investigates the relationship between glutamine- and IFN-γ-associated transcription in melanoma using bulk and single-cell data, finding that cellular composition explains much of the observed inverse correlation.

This study shows that blocking type 2 cytokines and PD1 enhances anti-tumor immunity by reprogramming immune cells in both in vitro and in vivo models.

This study identifies conserved neoantigens across species and tissues that elicit strong immune responses and suppress tumor growth through vaccination.

The paper shows that PD-1 blockade reinvigorates dysfunctional T cells by restoring translational activity, driving early antitumor immune responses in tumors.

The paper introduces statistical tools to analyze immune cluster patterns in prostate cancer and finds high-grade tumors show more immune infiltration and active immune features.

This study identifies SLC25A1 as a regulator of PD-L1 and type I interferon signaling via a mitochondrial pathway, influencing tumor immune response and immunotherapy efficacy.

This study shows that dietary methionine restriction enhances T cell metabolism and improves anti-PD1 checkpoint blockade efficacy in immunocompetent tumor models.